MAPK3 and neoplasm: To elucidate whether the anti-tumor effects of SNX2112 in PRCC cells are dependent on the PI3K/AKT and MEK/ERK1/2 signaling axis, cells with MET mutation (UOK345) as well as those with copy number gain of wild type MET (UOK342) were transfected with small interfering RNA (siRNA) for AKT1/2, ERK1/2 or non-targeting control.